New oral drug shows success in reversing hair loss

VDPHL01 is an orally administered, extended-release minoxidil formulation developed for pattern hair loss. In a double-blind, placebo-controlled late-stage trial of about 500 men with mild to moderate hair loss, hair growth was detectable by month two. Improvements in hair coverage were reported by 79% of once-daily patients and 86% of twice-daily patients. Total improvement reached about 30 to 33 hairs per square centimeter by month six. The trial reported positive efficacy and safety outcomes. Veradermics positions VDPHL01 as the first oral minoxidil formulation developed specifically for pattern hair loss and as a potential first FDA-approved non-hormonal oral treatment in the U.S. without cardiovascular side effects.

"“Dermatology has been treating hair loss with a drug borrowed from cardiology, in a formulation never intended for our patients, at doses we arrived at informally. VDPHL01 is the first oral minoxidil formulation developed specifically for pattern hair loss, and now the first to generate positive Phase 3 results of efficacy and safety.”"

"“Seventy-nine percent of once-daily patients and 86 percent of twice-daily patients reported improvement in hair coverage.”"

"“Veradermics gathered roughly 500 men with mild to moderate hair loss for their double-blind, placebo-controlled trial. The study saw hair growth was detectable by month two and a total improvement of between 30 and 33 hairs per square centimeter at month six.”"

"“Veradermics noted that if approved, VDPHL01 would become the first FDA-approved non-hormonal oral treatment in the U.S., particularly one without cardiovascular side effects.”"

Read at Fast Company